A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

• Published in: Gynecologic oncology Vol. 116; no. 3; pp. 332 - 334
• Main Authors: Rocereto, Thomas F, Brady, William E, Shahin, Mark S, Hoffman, James S, Small, Laurie, Rotmensch, Jacob, Mannel, Robert S
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2010
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Epithelial ovarian cancer; Fallopian cancer; Fallopian Tube Neoplasms - drug therapy; Female; GOG; Hematology, Oncology and Palliative Medicine; Humans; Kaplan-Meier Estimate; Middle Aged; Mifepristone; Mifepristone - adverse effects; Mifepristone - therapeutic use; Neoplasm Recurrence, Local - drug therapy; Obstetrics and Gynecology; Ovarian Neoplasms - drug therapy; Peritoneal Neoplasms - drug therapy; Primary peritoneal cancer; Mifepristone; Primary peritoneal cancer; Fallopian cancer; Epithelial ovarian cancer; GOG
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2009.10.071

Abstract Objective To evaluate the effectiveness and toxicity of mifepristone in patients with ovarian, peritoneal and fallopian tube cancers. Methods Patients with confirmed epithelial ovarian, peritoneal and fallopian tube cancers which were persistent or recurred in less then 1 year after primary chemotherapy were entered into this study. Patients were given mifepristone 200 mg by mouth daily for a 28 day cycle. The medication was stopped for unacceptable toxicity or tumor progression. Results Twenty-four patients were entered into the study. Twenty-two patients were evaluable for response. Only one patient had a partial response for a response rate of only 4.5% (90% confidence interval: 0.2%, 19.8%). Conclusion Mifepristone has not proven to be an effective agent in the treatment of patients with recurrent or persistent ovarian, peritoneal and fallopian tube cancers.